Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Study challenges role of BRCA1 mutation in prostate cancer initiation February 24, 2025 Single dose of MVA-BN vaccine shows 58% effectiveness against mpox September 11, 2024 Peer support program shows promise for cancer patients in Vietnam November 25, 2024